NVIDIA Corporation is a strong sell with a $27 price target by the end of 2027. Click here to read the latest analysis on ...

StoneCo shifts to credit/banking earnings with deposit funding and maturing loans. Read here for a detailed investment ...

Collegium Pharma (COLL) gets a bullish upgrade: strong profitability, raised 2026 guidance, and Jornay PM growth outlook. See ...

Relative performance for nearly all LifeSmart Portfolios benefited from underweight exposure to fixed income and, for most ...

Parnassus Growth Equity Fund (Investor Shares) returned 3.93% (net of fees) during the quarter, outperforming the Russell ...

Elastic stock analysis: wide moat, strong expansion and balance sheet, plus buyback. Valuation suggests ~56% upside to $108.8 ...

Compass/Anywhere Real Estate's merger and pocket listings strategy threaten Zillow's core listing advantage. Read why Z stock ...

PKW performed almost as well as S&P 500 since its inception. Read why I consider PKW ETF worth buying for those who look for ...

Nebius (NBIS) is a top 2026 AI stock pick—scalable GPU infrastructure poised to win as SaaS commoditizes. See growth, margin ...

The National Association of Realtors (NAR) pending home sales index experienced its largest monthly loss since 2020, falling ...

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea.

Cedar Creek Partners details high-alpha returns in the expert market via positions like Exco Resources and Phi Group. Read ...